Santoro F, Merlino F, Brancaccio D, Camerino I, Belli S, Cimmino A
Cells. 2025; 14(4).
PMID: 39996732
PMC: 11853379.
DOI: 10.3390/cells14040259.
Szivos L, Virga J, Meszar Z, Rostas M, Bako A, Zahuczki G
Brain Sci. 2024; 14(11).
PMID: 39595920
PMC: 11592374.
DOI: 10.3390/brainsci14111157.
Granados-Aparici S, Vieco-Marti I, Lopez-Carrasco A, Navarro S, Noguera R
iScience. 2024; 27(11):111231.
PMID: 39569369
PMC: 11576390.
DOI: 10.1016/j.isci.2024.111231.
Elser M, Vehlow A, Juratli T, Cordes N
Am J Cancer Res. 2023; 13(10):4597-4612.
PMID: 37970361
PMC: 10636682.
Vakhrushev A, Gruzdev D, Demin A, Levit G, Krasnov V
Molecules. 2023; 28(8).
PMID: 37110700
PMC: 10143838.
DOI: 10.3390/molecules28083467.
Integrin β3 Promotes Resistance to EGFR-TKI in Non-Small-Cell Lung Cancer by Upregulating AXL through the YAP Pathway.
Sun Q, Lu Z, Zhang Y, Xue D, Xia H, She J
Cells. 2022; 11(13).
PMID: 35805163
PMC: 9265629.
DOI: 10.3390/cells11132078.
Inhibition of angiogenesis and tumor progression of MK-0429, an integrin αvβ antagonist, on oral squamous cell carcinoma.
Nakagawa T, Ohta K, Naruse T, Sakuma M, Fukada S, Yamakado N
J Cancer Res Clin Oncol. 2022; 148(12):3281-3292.
PMID: 35713706
PMC: 9587112.
DOI: 10.1007/s00432-022-04100-3.
Integrin-αvβ3 as a Therapeutic Target in Glioblastoma: Back to the Future?.
Echavidre W, Picco V, Faraggi M, Montemagno C
Pharmaceutics. 2022; 14(5).
PMID: 35631639
PMC: 9144720.
DOI: 10.3390/pharmaceutics14051053.
The Effects of αvβ3 Integrin Blockage in Breast Tumor and Endothelial Cells under Hypoxia In Vitro.
Casali B, Gozzer L, Baptista M, Altei W, Selistre-de-Araujo H
Int J Mol Sci. 2022; 23(3).
PMID: 35163668
PMC: 8835904.
DOI: 10.3390/ijms23031745.
Anti-Cancer Effects of Cyclic Peptide ALOS4 in a Human Melanoma Mouse Model.
Levi B, Yacobovich S, Kirby M, Becker M, Agranyoni O, Redko B
Int J Mol Sci. 2021; 22(17).
PMID: 34502483
PMC: 8430629.
DOI: 10.3390/ijms22179579.
APLN/APLNR Signaling Controls Key Pathological Parameters of Glioblastoma.
Kalin R, Glass R
Cancers (Basel). 2021; 13(15).
PMID: 34359800
PMC: 8345670.
DOI: 10.3390/cancers13153899.
A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials.
Cruz Da Silva E, Mercier M, Etienne-Selloum N, Dontenwill M, Choulier L
Cancers (Basel). 2021; 13(8).
PMID: 33918704
PMC: 8069979.
DOI: 10.3390/cancers13081795.
Peptide-Based Strategies for Targeted Tumor Treatment and Imaging.
Ayo A, Laakkonen P
Pharmaceutics. 2021; 13(4).
PMID: 33918106
PMC: 8065807.
DOI: 10.3390/pharmaceutics13040481.
Visualization of Diagnostic and Therapeutic Targets in Glioma With Molecular Imaging.
Li D, Patel C, Xu G, Iagaru A, Zhu Z, Zhang L
Front Immunol. 2020; 11:592389.
PMID: 33193439
PMC: 7662122.
DOI: 10.3389/fimmu.2020.592389.
Are Integrins Still Practicable Targets for Anti-Cancer Therapy?.
Alday-Parejo B, Stupp R, Ruegg C
Cancers (Basel). 2019; 11(7).
PMID: 31336983
PMC: 6678560.
DOI: 10.3390/cancers11070978.
Metastasis inhibition in breast cancer by targeting cancer cell extravasation.
Cominetti M, Altei W, Selistre-de-Araujo H
Breast Cancer (Dove Med Press). 2019; 11:165-178.
PMID: 31114313
PMC: 6497883.
DOI: 10.2147/BCTT.S166725.
Shedding New Light on The Role of ανβ3 and α5β1 Integrins in Rheumatoid Arthritis.
Morshed A, Abbas A, Hu J, Xu H
Molecules. 2019; 24(8).
PMID: 31003546
PMC: 6515208.
DOI: 10.3390/molecules24081537.
Recombinant RGD-disintegrin DisBa-01 blocks integrin αβ and impairs VEGF signaling in endothelial cells.
Danilucci T, Santos P, Pachane B, Pisani G, Lino R, Casali B
Cell Commun Signal. 2019; 17(1):27.
PMID: 30894182
PMC: 6425665.
DOI: 10.1186/s12964-019-0339-1.
Urokinase-derived peptide UP-7 suppresses tumor angiogenesis and metastasis through inhibition of FAK activation.
Kim H, Naidansuren P, Lee S, Kim R, Lee S, Lee S
Oncotarget. 2018; 9(11):9951-9962.
PMID: 29515782
PMC: 5839413.
DOI: 10.18632/oncotarget.24131.
Integrins and Exosomes, a Dangerous Liaison in Cancer Progression.
Paolillo M, Schinelli S
Cancers (Basel). 2017; 9(8).
PMID: 28933725
PMC: 5575598.
DOI: 10.3390/cancers9080095.
